Dexcom announced today that its G6 continuous glucose monitor (CGM) is being worn by astronauts as part of the Polaris Dawn ...

Both of Abbott's over-the-counter CGMS are based on its popular FreeStyle Libre sensor technology, as Dexcom's prescription-free Stelo follows the popular G6 and G7 CGM technology for people who ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Both of Abbott's over-the-counter CGMS are based on its popular FreeStyle Libre sensor technology, as Dexcom's prescription-free Stelo follows the popular G6 and G7 CGM technology for people who ...

The Dexcom portfolio in the U.S. consists of the Dexcom G6 and Dexcom G7 Continuous Glucose ... A study was conducted to assess the sensor life where 77.9% of sensors lasted the full 15 days.

Instead of just a one-time test, Stelo provides an over-the-counter sensor that can collect data ... story but also a great data story. The Dexcom G6 Pro gave me insights into how my body was ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing ...

today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space as part of the Polaris Dawn mission, which launched this morning and aims to better ...

Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps ...

DexCom is one of the leaders in an industry with massive growth potential. The company is building a competitive advantage. Despite several risks, it could deliver substantial returns in the long ...